-葡萄糖共载体2抑制剂在肝硬化患者中使用
Fu-Shun Yen1, Ming-Chih Hou2,3, James Cheng-Chung Wei4,5,6
1Dr. Yen's Clinic, Taoyuan, Taiwan.
Diabetes/metabolism research and reviews
|July 23, 2025
概括
-葡萄糖共运输体2 (SGLT2) 抑制剂显著降低了2型糖尿病和肝硬化患者的死亡率,肝脏问题和心血管事件. 长时间使用进一步降低了这些风险,这表明SGLT2抑制剂是潜在的治疗选择.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 内分泌学 在内分泌学.
- 心脏病学 心脏病学
背景情况:
- 肝硬化和糖尿病 (DM) 是常见的并发症.
- 这些条件之间的相互作用可能导致肝脏和心血管的不良结果.
研究的目的:
- 调查使用-葡萄糖携运输体2 (SGLT2) 抑制剂对肝硬化和2型糖尿病患者的肝脏和心血管结果.
- 为了比较 SGLT2 抑制剂使用者与非使用者之间不补偿性肝硬化,肝衰竭,心血管事件和死亡率的风险.
主要方法:
- 一项使用台湾国家健康保险研究数据库 (2000-2021) 的全国性队列研究.
- 纳入标准:被诊断为2型糖尿病和肝硬化患者.
- 用多变量调整的考克斯比例危险模型来进行风险比较.
主要成果:
- 与非使用者相比,使用SGLT2抑制剂的患者具有较低的全因死亡风险 (aHR 0.47),不补偿性肝硬化 (aHR 0.67),肝衰竭 (aHR 0.58),肝综合征 (aHR 0.54) 和主要不良心血管事件 (aHR 0.80).
- 在使用SGLT2抑制剂的人群中,死亡率明显较低 (每1000人年为29.97人),而非使用者 (每1000人年为63.18人).
- 观察到剂量与反应的关系,较长时间的累积SGLT2抑制剂使用与进一步降低死亡率和不补偿性肝硬化风险有关.
结论:
- 使用SGLT2抑制剂与补偿性肝硬化和2型糖尿病患者的肝脏和心血管结果显著改善有关.
- 在这种高风险患者群体中,SGLT2抑制剂代表了管理2型糖尿病的有希望的治疗选择.
- 进一步的研究可能会探索这些保护作用背后的具体机制.
更多相关视频
04:14Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019
12.1K
08:41Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
Published on: March 24, 2023
1.3K
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
265
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
265
Dipeptidyl Peptidase 4 Inhibitors
262
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
262
Oral Hypoglycemic Agents: Biguanides and Glitazones
305
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
305
Glucose Transporters
24.2K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
24.2K
Secondary Active Transport
124.6K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
124.6K
Oral Hypoglycemic Agents: Glinides
263
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
263
